Review
Pharmacology & Pharmacy
Yi Han Chen, Xin Yu Wang, Xin Jin, Zi Yang, Jianguang Xu
Summary: Primary Sjogren's syndrome (pSS) is a systemic autoimmune disease characterized by dry eyes and dry mouth. B-cell hyperactivity is a key feature of the disease, leading to efforts to optimize B-cell targeted therapy. Monoclonal antibodies like rituximab (RTX) may be initiated in patients with severe, refractory systemic disease, although clinical trial data on RTX efficacy remains controversial.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Simon J. Bowman, Robert Fox, Thomas Doerner, Xavier Mariette, Athena Papas, Thomas Grader-Beck, Benjamin A. Fisher, Filipe Barcelos, Salvatore De Vita, Hendrik Schulze-Koops, Robert J. Moots, Guido Junge, Janice N. Woznicki, Monika A. Sopala, Wen-Lin Luo, Wolfgang Hueber
Summary: This study demonstrated the safety and efficacy of ianalumab in patients with moderate to severe primary Sjogren's syndrome. The drug showed dose-related reduction in disease activity and was well tolerated.
Review
Biochemistry & Molecular Biology
Nicoletta Del Papa, Antonina Minniti, Wanda Maglione, Francesca Pignataro, Roberto Caporali, Claudio Vitali
Summary: Primary Sjogren's syndrome is a systemic autoimmune disorder with heterogeneous features, and the development of comprehensive outcome measures is crucial for successful evaluation of therapeutic efficacy in treatment trials.
Article
Medicine, General & Internal
Wenxin Cai, Ru Li, Jing He, Miao Shao, Zhanguo Li
Summary: In this case report, a 55-year-old woman was diagnosed with coexisting neurosarcoidosis and Sjogren's syndrome. The patient presented with erythema nodosum, motor and sensory impairment, dry eyes, and dry mouth. The clinical and laboratory features fulfilled the classification criteria for both sarcoidosis and Sjogren's syndrome. This case extends our understanding of the overlap between Sjogren's syndrome and sarcoidosis and provides valuable reference for clinical diagnosis.
JOURNAL OF CLINICAL MEDICINE
(2022)
Review
Immunology
Elisabeth Maeland, Samira T. Miyamoto, Daniel Hammenfors, Valeria Valim, Malin V. Jonsson
Summary: Sjogren's syndrome is an autoimmune disease that affects the salivary and lacrimal glands, with fatigue being a common symptom. While the mechanisms involved in fatigue in SS are poorly understood, exercise and neuromodulation techniques have shown positive effects in reducing fatigue.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Rheumatology
Raphaele Seror, Saaeha Rauz, Marjolaine Gosset, Simon J. Bowman
Summary: In the past decades, international collaboration efforts have led to the development of consensual clinical indexes for assessing different facets of primary Sjögren's syndrome (pSS). Objective measures have been developed to quantify the importance and consequences of ocular and oral dryness, some specific to pSS. The emergence of new targeted therapies has increased emphasis on clinical trial design in pSS.
Article
Immunology
Theodoros Androutsakos, Theodoros A. Voulgaris, Athanasios-Dimitrios Bakasis, Maria-Loukia Koutsompina, Loukas Chatzis, Ourania D. Argyropoulou, Vasilis Pezoulas, Dimitrios I. Fotiadis, George Papatheodoridis, Athanasios G. Tzioufas, Andreas V. Goules
Summary: This study explored the occurrence of liver fibrosis (LF) in primary Sjogren syndrome (pSS) patients in the context of non-alcoholic fatty liver disease (NAFLD). The results showed that pSS patients had a lower prevalence of liver steatosis and significant liver fibrosis compared to the comparators. Advanced LF was significantly associated with older age, higher LS, greater BMI, and disease status, with age being identified as an independent LF risk factor.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Perrine Soret, Christelle Le Dantec, Emiko Desvaux, Nathan Foulquier, Bastien Chassagnol, Sandra Hubert, Christophe Jamin, Guillermo Barturen, Guillaume Desachy, Valerie Devauchelle-Pensec, Cheiema Boudjeniba, Divi Cornec, Alain Saraux, Sandrine Jousse-Joulin, Nuria Barbarroja, Ignasi Rodriguez-Pinto, Ellen De Langhe, Lorenzo Beretta, Carlo Chizzolini, Laszlo Kovacs, Torsten Witte, Eleonore Bettacchioli, Anne Buttgereit, Zuzanna Makowska, Ralf Lesche, Maria Orietta Borghi, Javier Martin, Sophie Courtade-Gaiani, Laura Xuereb, Mickael Guedj, Philippe Moingeon, Marta E. Alarcon-Riquelme, Laurence Laigle, Jacques-Olivier Pers, Barbara Vigone, Alain Saraux, Valerie Devauchelle-Pensec, Divi Cornec, Bernard Lauwerys, Julie Ducreux, Anne-Lise Maudoux, Carlos Vasconcelos, Ana Tavares, Esmeralda Neves, Raquel Faria, Mariana Brandao, Ana Campar, Antonio Marinho, Fatima Farinha, Isabel Almeida, Miguel Angel Gonzalez-Gay Mantecon, Ricardo Blanco Alonso, Alfonso Corrales Martinez, Ricard Cervera, Gerard Espinosa, Rik Lories, Nicolas Hunzelmann, Doreen Belz, Niklas Baerlecken, Georg Stummvoll, Michael Zauner, Michaela Lehner, Eduardo Collantes, Rafaela Ortega-Castro, Ma Angeles Aguirre-Zamorano, Ma Carmen Castro-Villegas, Yolanda Jimenez Gomez, Norberto Ortego, Maria Concepcion Fernandez Roldan, Enrique Raya, Inmaculada Jimenez Moleon, Enrique de Ramon, Isabel Diaz Quintero, Pier Luigi Meroni, Maria Gerosa, Tommaso Schioppo, Carolina Artusi, Sonja Dulic, Gabriella Kadar, Falk Hiepe, Velia Gerl, Silvia Thiel, Manuel Rodriguez Maresca, Antonio Lopez-Berrio, Rocio Aguilar-Quesada, Hector Navarro-Linares, Yiannis Ioannou, Chris Chamberlain, Jacqueline Marovac, Marta Alarcon Riquelme, Tania Gomes Anjos, Concepcion Maranon, Lucas Le Lann, Quentin Simon, Benedicte Rouviere, Nieves Varela, Brian Muchmore, Aleksandra Dufour, Montserrat Alvarez, Jonathan Cremer, Chary Lopez-Pedrera, Velia Ger, Laleh Khodadadi, Qingyu Cheng, Aurelie De Groof, Elena Trombetta, Tianlu Li, Damiana Alvarez-Errico, Katja Kniesch, Nancy Azevedo, Sambasiva Rao, Pierre-Emmanuel Jouve
Summary: Researchers combined data from a large cohort of patients and healthy controls to identify biomarkers that distinguish patient subgroups in order to improve understanding of Sjogren's syndrome and facilitate drug development.
NATURE COMMUNICATIONS
(2021)
Article
Medicine, General & Internal
Xinyao Zhou, Haodong Xu, Jinzhou Chen, Hengbo Wu, Yi Zhang, Feng Tian, Xiaopo Tang, Huadong Zhang, Lin Ge, Kesong Li, Wen Jiang, Zhishun Liu, Quan Jiang
Summary: In patients with primary Sjogren's syndrome, acupuncture did not significantly improve symptoms compared to placebo. However, interesting discoveries and possible underlying reasons were observed.
FRONTIERS IN MEDICINE
(2022)
Article
Immunology
Jessica Tarn, Dennis Lendrem, Michael Barnes, John Casement, Wan-Fai Ng
Summary: This study investigated the polypharmacy and comorbidities in patients with Primary Sjogren's Syndrome (PSS) using data from the UK Primary Sjogren's Syndrome Registry. The results showed differences in comorbidities and medication use among different PSS subgroups. Age and BMI were associated with increased comorbidity and polypharmacy scores. These findings have potential implications for disease management and clinical trial design.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Alan N. Baer, Jacques-Eric Gottenberg, E. William St Clair, Takayuki Sumida, Tsutomu Takeuchi, Raphaele Seror, Gary Foulks, Marleen Nys, Sumanta Mukherjee, Robert Wong, Neelanjana Ray, Hendrika Bootsma
Summary: In adults with active primary Sjogren's syndrome, treatment with abatacept did not demonstrate significant clinical efficacy compared to placebo, despite evidence of biological activity.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Review
Rheumatology
Roald Omdal, Svein Ivar Mellgren, Katrine Braekke Norheim
Summary: Chronic fatigue, pain, and depression are common in patients with primary Sjogren's syndrome and have a significant impact on their quality of life. These phenomena are not only present in primary Sjogren's syndrome but also in other systemic inflammatory autoimmune diseases, cancer, and neurodegenerative diseases.
Article
Immunology
Gillen Hatemi, Yusuf Yazici
Summary: Disease assessment in Behcet syndrome is challenging due to its heterogeneous disease course and involvement of multiple organs with varying treatment response. Recent improvements have been made in outcome measures, including the development of a Core Set of Domains and novel instruments for assessing specific organs and overall damage. This review focuses on the current state of outcome measures in Behcet syndrome, unmet needs, and a research agenda for the development of standardized and validated assessment tools.
CLINICAL IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Xiaoyan Wang, Xiang Lin, Yingying Su, Hao Wang
Summary: This study assessed the efficacy and safety of biologics in improving salivary gland function in pSS patients through clinical trials. The results showed that biologics did not have a significant effect on improving salivary gland function in pSS patients, but were more effective in early-stage patients. The safety of biologics treatment needs to be addressed in future clinical trials.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Rheumatology
Stephanie Finzel, Sandrine Jousse-Joulin, Felicie Costantino, Petra Hanova, Alojzija Hocevar, Annamaria Iagnocco, Helen Keen, Esperanza Naredo, Sarah Ohrndorf, Wolfgang A. Schmidt, Maria Antonietta D'Agostino, Lene Terslev, George A. Bruyn
Summary: The consensually agreed US definitions and scoring system for major salivary gland assessment showed high reliability in patients with SS, while the reliability of the Sjogren's signature was moderate.
Article
Rheumatology
Paolo Delvino, Federica Sardanelli, Sara Monti, Pascal Cohen, Xavier Puechal, Luc Mouthon, Carlomaurizio Montecucco, Loic Guillevin, Benjamin Terrier
Summary: This study assessed the prevalence and impact of different levels of disease activity on damage accrual in patients with GPA and MPA. The results showed that more than 60% of patients achieved prolonged remission, which was associated with better long-term outcomes.
ARTHRITIS CARE & RESEARCH
(2023)
Article
Rheumatology
Michael Hughes, Suiyuan Huang, Juan Jose Alegre-Sancho, Patricia E. Carreira, Merete Engelhart, Eric Hachulla, Joerg Henes, Eduardo Kerzberg, Maria Rosa Pozzi, Gabriela Riemekasten, Vanessa Smith, Gabriella Szucs, Marie Vanthuyne, Elisabetta Zanatta, Oliver Distler, Armando G. Gabrielli, Anna-Maria Hoffmann-Vold, Virginia D. Steen, Dinesh Khanna
Summary: This study aimed to investigate the prevalence and characteristics of late skin fibrosis in systemic sclerosis (SSc). The study found that late skin fibrosis is not uncommon in SSc, and different patterns of development exist among patients. Patients with lower baseline mRSS and lcSSc are more likely to develop late skin fibrosis. Anti-Scl-70 is associated with progression from lcSSc to dcSSc, while anticentromere antibodies have a protective effect.
Article
Rheumatology
Yann Nguyen, Cecile M. Yelnik, Nathalie Morel, Romain Paule, Romain Stammler, Leo Placais, Karim Sacre, Bertrand Godeau, Helene Maillard, David Launay, Sandrine Morell-Dubois, Anastasia Dupre, Guillaume Lefevre, Cecile Devloo, Virginie Dufrost, Ygal Benhamou, Herve Levesque, Gaelle Leroux, Jean-Charles Piette, Luc Mouthon, Eric Hachulla, Marc Lambert, Veronique Le Guern, Nathalie Costedoat-Chalumeau
Summary: This study used unsupervised clustering analysis to identify four homogeneous phenotypic subgroups among APS patients, primarily involving venous, arterial, SLE or other autoimmune disease-associated, and arterial microthrombotic phenotypes. These findings may be explained by heterogeneous pathophysiological mechanisms.
Article
Rheumatology
Michele Iudici, Denis Mongin, Elise Siegert, Patricia E. Carreira, Joerg Distler, Joerg Henes, Elisabetta Zanatta, Eric Hachulla, Giacomo De Luca, Carolina de Souza Mueller, Tania Santiago, Jose-Luis Tandaipan, Breno Valdetaro Bianchi, Maria De Santis, Anna-Maria Hoffmann-Vold, Armando Gabrielli, Oliver Distler, Delphine Sophie Courvoisier
Summary: The study aimed to estimate the prevalence of long-term exposure to glucocorticoids (GCs) among SSc patients and identify factors associated with prescribing practices over time and across countries. The results showed that the utilization of GCs is widespread and long-term in SSc patients, with significant variations between countries and within-country. However, there has been a gradual decrease in their utilization.
Article
Rheumatology
Alain Lescoat, Doerte Huscher, Nils Schoof, Paolo Airo, Jeska De Vries-Bouwstra, Gabriela Riemekasten, Eric Hachulla, Andrea Doria, Edoardo Rosato, Nicolas Hunzelmann, Carlomaurizio Montecucco, Armando Gabrielli, Anna-Maria Hoffmann-Vold, Oliver Distler, Jennifer Ben Shimol, Maurizio Cutolo, Yannick Allanore
Summary: The prevalence and characteristics of SSc-associated interstitial lung disease (SSc-ILD) vary between geographical regions. This study aimed to explore the differences in prevalence, phenotype, treatment, and prognosis in patients with SSc-ILD from different regions in the EUSTAR database. The results showed significant variations in clinical characteristics, survival rates, and treatment approaches among different regions.
Article
Rheumatology
Sebastien Sanges, Lisa Rice, Ly Tu, Eleanor Valenzi, Jean-Luc Cracowski, David Montani, Julio C. Mantero, Camille Ternynck, Guillemette Marot, Andreea M. Bujor, Eric Hachulla, David Launay, Marc Humbert, Christophe Guignabert, Robert Lafyatis
Summary: This study examined the serum proteome of patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) and identified two proteins that were significantly correlated with pulmonary vascular resistance (PVR), potentially providing biomarkers for earlier diagnosis and treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Amalia Colalillo, Anna-Maria Hoffmann-Vold, Chiara Pellicano, Antonella Romaniello, Armando Gabrielli, Eric Hachulla, Vanessa Smith, Carmen-Pilar Simeon-Aznar, Ivan Castellvi, Paolo Airo, Marie-Elise Truchetet, Elise Siegert, Oliver Distler, Edoardo Rosato
Summary: This study evaluated the predictive role of the echocardiography-derived TAPSE/sPAP ratio for pulmonary hypertension (PH) diagnosis and mortality. The study found that a TAPSE/sPAP ratio < 0.55 mm/mmHg is a predictive risk factor for PH, and a TAPSE/sPAP ratio <= 0.32 mm/mmHg is a predictive risk marker for all-cause mortality.
AUTOIMMUNITY REVIEWS
(2023)
Article
Medicine, General & Internal
Cecile Philippoteaux, Valentine Deprez, Aurore Nottez, Emeline Cailliau, Eric Houvenagel, Xavier Deprez, Peggy Philippe, Tristan Pascart, Rene-Marc Flipo, Vincent Goeb, Jean-Guillaume Letarouilly
Summary: This study compared the baseline characteristics of rheumatoid arthritis (RA) patients initiating Baricitinib (BARI) or Tofacitinib (TOFA) before and after the European Medicine Agency (EMA) issued warnings on venous thromboembolism (VTE) risk. The study also compared the real-world persistence with these two drugs. The results showed no significant change in patient characteristics after the EMA's warnings, but a lower proportion of VTE history was observed in patients initiating the drugs after May 2019.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Cloe Comarmond, Elodie Drumez, Julien Labreuche, Eric Hachulla, Thierry Thomas, Rene-Marc Flipo, Raphaelle Seror, Jerome Avouac, Nathalie Balandraud, Renaud Desbarbieux, Renaud Felten, Melanie Gilson, Marie-Hlene Guyot, Ambre Hittinger-Roux, Thao Pham, Myriam Renard, Nicolas Roux, Vincent Sobanski, Anne Tournadre, Christophe Richez, Patrice Cacoub
Summary: This study investigated whether RMD patients receiving anti-IL6 therapy have less severe forms of COVID-19 and better outcomes. Retrospective analysis of the French RMD COVID-19 cohort data showed that the severity of COVID-19 was lower in the anti-IL6 group, but there were no significant differences in the evolution of COVID-19 between the groups.
JOURNAL OF TRANSLATIONAL AUTOIMMUNITY
(2023)
Article
Rheumatology
Alessia Alunno, Tadej Avcin, Catherine Haines, Sofia Ramiro, Francisca Sivera, Sara Badreh, Xenofon Baraliakos, Johannes W. J. Bijlsma, Frank Buttgereit, Kaushik Chaudhuri, Jose A. P. Da Silva, Jean Dudler, Ricardo J. O. Ferreira, Tania Gudu, Eric Hachulla, Mette Holland-Fischer, Annamaria Iagnocco, Tue Wenzel Kragstrup, Gyoergy Nagy, Vasco C. Romao, Simon R. Stones, Marloes van Onna, Christopher J. Edwards
Summary: This study aimed to define competences and standards for the training of rheumatologists. Through collaboration and analysis of international training documents, an overall framework, 7 domains, 8 core themes, and 28 competences were established. The results suggest that these standards can contribute to harmonizing rheumatology training across European countries.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Nihel Khoudour, Florence Delestre, Fabienne Jabot-Hanin, Anne Jouinot, Juliette Nectoux, Franck Letouneur, Brigitte Izac, Michel Vidal, Loic Guillevin, Xavier Puechal, Pierre Charles, Benjamin Terrier, Benoit Blanchet
Summary: This study examines the relationship between rituximab plasma concentration, genetic polymorphisms, and clinical outcomes in ANCA-associated vasculitides. The results suggest that drug monitoring can be useful in individualizing rituximab administration.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Maxime Samson, Herve Devilliers, Sara Thietart, Pierre Charles, Christian Pagnoux, Pascal Cohen, Alexandre Karras, Luc Mouthon, Benjamin Terrier, Xavier Puechal, Loic Guillevin
Summary: The study aimed to develop a score for assessing the likelihood of relapse in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Long-term follow-up data from patients with GPA and MPA included in five randomized controlled trials were pooled. Variables associated with relapse were identified and used to build a score, which was validated in an independent cohort.
Article
Endocrinology & Metabolism
Marie Doussiere, Claire Jesson, Laetitia Diep, Jimmy Menis, Corinne Fauvet, Patrice Fardellone, Vincent Goeb
Summary: This study describes the characteristics of 337 patients seen by the fracture liaison service of the Amiens University Hospital for at least two osteoporotic fractures between 2009 and 2019. Results showed that recurrent fracture occurs rapidly after the index fracture. Rheumatological and therapeutic managements are not sufficient, mainly because of cognitive disorders or patients' refusal.
OSTEOPOROSIS INTERNATIONAL
(2023)
Meeting Abstract
Rheumatology
Louai Zaidan, Noemie Le Gouellec, Eric Hachulla, Luc Mouthon, Francois Jerome Authier
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)
Article
Rheumatology
T. Rabin, G. De Marco, S. R. Dubash, F. Shuweihdi, H. Marzo-Ortega, P. Emery, F. Ponchel, V. Goeb
Summary: This pilot study analyzed the abnormalities in circulating lymphocyte subsets in axial spondyloarthritis (axSpA) and investigated their potential association with the response to biologic disease-modifying anti-rheumatic drugs (b-DMARDs). The results showed dysregulation of lymphocyte subsets in axSpA and different associations with clinical response to IL17i and TNFi.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2023)